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Evaluation of a Weight-Adjusted Single-Bolus Plasminogen
Activator in Patients With Myocardial Infarction
A Double-Blind, Randomized Angiographic Trial
of Lanoteplase Versus Alteplase
Peter den Heijer, MD; Frank Vermeer, MD; Ettore Ambrosioni, MD; Zygmunt Sadowski, MD;
Jose´ L. Lo´pez-Sendo´n, MD; Rainer von Essen, MD; Philippe Beaufils, MD; Udho Thadani, MD;
Jennifer Adgey, MD; Luc Pierard, MD; Jeffrey Brinker, MD; Richard F. Davies, MD;
Richard W. Smalling, MD; Lars Wallentin, MD; Abraham Caspi, MD; Andreas Pangerl, MD;
Linda Trickett, BSc; Cynthia Hauck, MS; David Henry, PhD; Paul Chew, MD;
on behalf of the InTIME Investigators*
Background—Lanoteplase (nPA) is a rationally designed variant of tissue plasminogen activator with greater fibrinolytic
potency and slower plasma clearance than alteplase.
Methods and Results—InTIME (Intravenous nPA for Treatment of Infarcting Myocardium Early), a multicenter, double-blind,
randomized, double-placebo angiographic trial, evaluated the dose-response relationship and safety of single-bolus,
weight-adjusted lanoteplase. Patients (n5602) presenting within 6 hours of acute myocardial infarction were randomized and
treated with either a single-bolus injection of lanoteplase (15, 30, 60, or 120 kU/kg) or accelerated alteplase. The primary
objective was to determine TIMI grade flow at 60 minutes. Angiographic assessments were also performed at 90 minutes and
on days 3 to 5. Follow-up was continued for 30 days. Lanoteplase achieved its primary objective, demonstrating a
dose-response in TIMI grade 3 flow at 60 minutes (23.6% to 47.1% of subjects, P,0.001). Similar results were observed at
90 minutes (26.1% to 57.1%, P,0.001). At 90 minutes, coronary patency (TIMI 2 or 3) increased across the dose range up
to 83% of subjects at 120 kU/kg lanoteplase compared with 71.4% with alteplase. Thus, at this dose, lanoteplase was superior
to alteplase in restoring coronary patency (difference, 12%; 95% CI, 1% to 23%). The early safety experience in this study
suggests that lanoteplase was well tolerated at all doses with safety comparable to that of alteplase.
Conclusions—Lanoteplase, a single-bolus, weight-adjusted agent, increased coronary patency at 60 and 90 minutes in a
dose-dependent fashion. Coronary patency at 90 minutes was achieved more frequently with 120 kU/kg lanoteplase than
alteplase. In this study, safety with lanoteplase and alteplase was comparable. InTIME-II, a worldwide mortality trial,
will evaluate efficacy and safety with this promising new agent. (Circulation. 1998;98:2117-2125.)
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Thrombolytic therapy reduces mortality in acute myocar-dial infarction (AMI).1–3 Time to treatment and achieve-
ment of complete reperfusion (TIMI grade 3 flow) are critical
factors.4,5 Early treatment and complete TIMI grade 3 flow
have been facilitated by faster delivery regimens for acceler-
ated alteplase3 and double-bolus reteplase.6–8 Simpler effec-
tive regimens, such as a single-bolus injection, may offer
additional benefits through earlier achievement of reperfusion
and by reduction in the risk of dosing errors.
Efforts to improve thrombolytic efficacy are tempered by
the risk of serious bleeding, particularly hemorrhagic stroke.
As the use of thrombolytic agents has expanded to include
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more elderly patients, women, and patients with hyperten-
sion, there is a suggestion of increased hemorrhagic stroke.9
Use of a fully weight-adjusted dose may optimize the
risk-benefit ratio with thrombolytic therapy.
Lanoteplase (novel plasminogen activator, nPA) is a ratio-
nally designed variant of wild-type tissue plasminogen acti-
vator (tPA) developed to achieve greater fibrinolytic potency
and prolonged plasma half-life. Lanoteplase does not contain
the fibronectin fingerlike and epidermal growth factor do-
mains of wild-type tPA, accounting for its slower clear-
ance.10–12 Like alteplase, lanoteplase has enhanced fibrinolytic
activity in the presence of fibrin-related plasminogen. Despite
deletion of the fingerlike domain, lanoteplase retains some
fibrin specificity relative to streptokinase and urokinase. In
addition, an asparagine-to-glutamine change was made at
residue 117 to prevent this glycosylation site from being
occupied.13 These modifications allow delivery of effective
thrombolytic therapy as a single 2- to 4-minute injection. In
human volunteers, the half-life for plasminogen activation
activity is '37611 minutes, which permits single-bolus
dosing.14
InTIME (Intravenous nPA for Treatment of Infarcting
Myocardium Early) was a multicenter (Europe and North
America), double-blind, randomized, double-placebo dose-
ranging study comparing 4 doses of lanoteplase with accel-
erated alteplase. The primary objective of InTIME was to
determine whether single-bolus lanoteplase restored complete
coronary blood flow (TIMI grade 3) in a dose-related fashion
at 60 minutes after initiation of therapy in patients presenting
within 6 hours of suspected AMI. The preliminary safety and
tolerability profile of lanoteplase was also evaluated. Addi-
tional objectives of the study included evaluation of TIMI
grade 3 flow, of coronary patency (TIMI grade 2 and TIMI
grade 3 flow) at 90 minutes after initiation of therapy, and of
angiographic reocclusion on days 3 to 5 after initiation of
therapy. The predefined composite end point of unfavorable
clinical outcome at 30 days was also evaluated.
Methods
Study Population
Men and postmenopausal or surgically sterile women between the
ages of 18 and 80 years, presenting within 6 hours of suspected AMI,
were eligible for the study if the following criteria were met:
ischemic symptoms lasting $20 minutes, ST-segment elevation of
$0.1 mV in 2 contiguous limb leads or $0.2 mV in 2 contiguous
precordial leads or new left bundle-branch block, and ability to
receive study medication within 6 hours of symptom onset and to
undergo coronary angiography within 60 minutes after starting study
medication.
Patients were excluded if any of the following conditions were
present: bleeding diathesis; active or recent internal bleeding; history
of cerebrovascular accident; intracranial neoplasm, arteriovenous
malformation, or aneurysm; systolic blood pressure $180 mm Hg;
diastolic blood pressure $110 mm Hg; recent major surgery, trauma,
or cardiopulmonary resuscitation; likelihood of left heart thrombus;
acute pericarditis or subacute bacterial endocarditis; significant liver
or renal disease; oral anticoagulation; Killip class IV heart failure;
recent revascularization; history or symptoms of aortic dissection; or
any other medical condition that would interfere with study partici-
pation or produce significant risk to the patient. The protocol was
TABLE 1. Demographic Characteristics of 602 Patients Who Received Lanoteplase or
Accelerated Alteplase
Lanoteplase Dose (kU/kg)
Characteristic 15 30 60 120 Alteplase
No. of patients 123 109 123 123 124
Mean age, y6SD 59.4611.0 59.7610.2 59.2611.3 58.3610.4 59.1611.3
Men, % 80 78 85 79 84
Mean delay before treatment, h6SD 3.161.5 3.161.3 3.061.3 3.161.3 3.261.3
Prior MI, % 13.0 10.1 21.1 15.4 14.5
Killip class, %
I 93 93 93 93 92
II–IV 8 7 7 8 8
MI location, %
Anterior 25 24 21 15 23
Inferior 31 40 31 35 31
Multiple 37 30 42 43 39
IRA location, %
LAD 37 38 36 35 43
RCA 44 50 41 50 45
LCx 15 10 19 11 8
Multiple 0 0 1 1 0
None 2 1 1 1 0
Other 3 1 3 2 4
MI indicates myocardial infarction; IRA, infarct-related artery; LAD, left anterior descending coronary artery; RCA,
right coronary artery; and LCx, left circumflex artery.
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approved by local ethics committees, and informed consent was
obtained from all patients.
Treatment Protocol
Patients were randomized to receive 1 of 4 doses of lanoteplase and
the alteplase placebo or accelerated alteplase and the lanoteplase
placebo in a 1:1:1:1:1 ratio. All patients received only 1 active
thrombolytic. The sequence of the lanoteplase (or placebo) single
bolus or alteplase (or placebo) bolus was also randomized. The 30-
and 60-minute infusions of alteplase or placebo were always given
last. Lanoteplase was administered as a weight-adjusted dose of 15,
30, 60, or 120 kU/kg (not to exceed 12 000 kU). Lanoteplase or its
matching placebo was administered as a split single bolus (due to
provision of drug in 2 vials to allow full dose range) over 2 to 4
minutes. Alteplase or its matching placebo was administered accord-
ing to the accelerated regimen from GUSTO3; 15 mg was given by
intravenous bolus followed by doses of 0.75 mg/kg (not to exceed 50
mg) over 30 minutes, then 0.5 mg/kg (not to exceed 35 mg) over 60
minutes.
Aspirin 150 to 325 mg/d and heparin 5000 U by intravenous bolus
followed by 1000 U/h for at least 48 hours and adjusted to activated
partial thromboplastin time of 60 to 85 seconds were initiated before
study medication. Conventional antianginal therapy, long-acting
nitrates, calcium channel blockers, b-blockers, and standard care
were also initiated. Investigational treatments and devices were not
permitted within 30 days before or during the study. Other
thrombolytic agents were not permitted during the study.
Study End Points
Primary and secondary end points were prospectively determined.
Angiographic evaluations of TIMI grade flow in the infarct-related
artery were obtained 60 minutes (primary end point) and 90 minutes
(secondary end point) after initiation of study medication. Another
coronary angiogram was required between days 3 and 5, unless
revascularization was performed or the initial TIMI grade was 0 or
1. The Angiographic Core Laboratory (Cleveland Clinic, Cleveland,
Ohio) evaluated all angiograms in a blinded fashion. Patency of the
infarct-related artery was classified according to TIMI criteria.15
Brief physical examinations, laboratory tests, and 12-lead ECGs
were performed daily during hospitalization to monitor patients for
myocardial reinfarction, heart failure, recurrent ischemic symptoms,
coronary revascularization, bleeding, and other adverse events. The
presence of these events was also assessed on day 30 by brief
physical examination or telephone interview. Composite clinical
outcome was defined as death, reinfarction, major bleeding, or heart
failure within 30 days.
Myocardial reinfarction was defined by the presence of 2 of the
following conditions occurring .18 hours after index AMI: chest
pain lasting $20 minutes not relieved by nitroglycerin, new ST-
segment elevation of $0.1 mV or new abnormal Q waves, and serum
creatinine kinase (CK) that was more than twice the upper limit of
normal and .50% above the lowest CK level from the index AMI.
Heart failure was defined as congestion on chest radiograph without
evidence of noncardiac cause, plus at least 2 of the following:
midlung rales not cleared by coughing, mean pulmonary capillary
wedge pressure $18 mm Hg and cardiac index #2.4 L z min21 z m22,
and new use or increased dose of furosemide or bumetanide.
Recurrent ischemic symptoms were defined as chest, neck, or arm
discomfort lasting $1 minute, which was relieved by nitroglycerin
and was associated with new horizontal or downsloping ST-segment
depression. Stroke was diagnosed by investigators on clinical
grounds.
Bleeding was classified according to GUSTO criteria.3 Major
bleeding was defined as documented hemorrhagic stroke or bleeding
resulting in hemodynamic compromise and requiring transfusion of
packed red blood cells or other intervention. Moderate bleeding was
defined as an event requiring transfusion of packed red blood cells,
but one that was not accompanied by hemodynamic compromise.
Mild bleeding did not require transfusion of packed red blood cells
and was not accompanied by hemodynamic compromise.
Statistical Analysis
Calculations of sample size revealed that 107 patients were needed in
each group to detect a 20% increment in complete reperfusion (from
40% to 60%) across the 15- to 120-kU/kg dose range at a power of
85% and significance level (2-tailed) of 0.05. This calculation was
based on logistic regression and on the assumption of a linear
relationship to dose. To accommodate missing data and a planned
Figure 1. Dose-response effect of lanoteplase (15, 30, 60, and
120 kU/kg) and accelerated alteplase on normal coronary perfusion
(TIMI grade 3) at 60 minutes in patients with suspected AMI.
TABLE 2. TIMI Grade at 60 Minutes in Patients Randomized to Receive Lanoteplase or
Accelerated Alterplase
TIMI Grade
No. of Patients (%)
Lanoteplase Dose (kU/kg)
Alteplase
(n5107)15 (n5110) 30 (n595) 60 (n5109) 120 (n5102)
Failure* 0 (0) 0 (0) 1 (0.9) 1 (1.0) 0 (0)
0 40 (36.4) 36 (37.9) 23 (21.1) 22 (21.6) 27 (25.2)
1 10 (9.1) 3 (3.2) 10 (9.2) 6 (5.9) 9 (8.4)
2 34 (30.9) 28 (29.5) 27 (24.8) 25 (24.5) 31 (29.0)
3 26 (23.6) 28 (29.5) 48 (44.0) 48 (47.1) 40 (37.4)
Difference [95% CI] from
15 kU/kg NA 5.8 [26.3, 18.0] 20.4 [8.2, 32.6] 23.4 [10.9, 35.9] NA
Alteplase 213.7 [225.9, 21.6] 27.9 [220.9, 5.1] 6.7 [26.4, 19.7] 9.7 [23.7, 23.0] NA
NA indicates not applicable.
*Failure because of death or cardiovascular reason.
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interim analysis, the sample size was adjusted to 118 per group, for
a total of 590 patients.
All patients who received study medication were included in the
safety analysis. Patients were included in the efficacy analysis
whenever possible on the basis of the availability of complete
angiographic data. For the day 3 to 5 angiographic assessment,
patients were also included if the assessment was performed on day
6. (Day 1 was defined in the protocol as the day the study treatment
was given. To capture data in cases in which investigators interpreted
day 5 as the fifth day after treatment [day 6], the angiographic
analysis was expanded to include angiographic assessments on day
6.) If angiographic data were missing because of death or cardiovas-
cular reasons (eg, revascularization), patients were considered to be
treatment failures. If data were missing for other reasons (eg, usually
failure to obtain assessment within the specified time window after
initiation of study medication or to indicate time of assessment),
patients were excluded from the efficacy analysis.
Logistic regression was used to test for the presence of a linear
relationship between the log odds of a TIMI grade 3 response and
lanoteplase dose, expressed on the natural log scale. Departures from
linearity were assessed by comparing (at the 0.10 significance level)
the difference in log likelihood obtained from this linear model and
from a model not including the linearity assumption. Estimates of
pairwise differences (and 95% CIs) were calculated for the differ-
ence in response rates for each lanoteplase dose group versus the
low-dose lanoteplase group and versus the alteplase group.
Results
A total of 613 patients were enrolled by 88 investigators from
13 countries between March and November 1996. Eleven
patients were not included in the efficacy analysis because
treatment was not received. Demographic characteristics of
the remaining 602 patients, shown in Table 1, were similar
among treatment groups. One patient experienced a second
AMI 161 days after the index AMI and was randomized and
treated a second time; data from the second exposure (lanote-
plase 120 kU/kg) are included in the safety analysis as a
separate case but are excluded from the efficacy analysis.
Efficacy
Primary Efficacy Outcome Measure
There was a statistically significant increase in the proportion
of subjects with TIMI grade 3 flow at 60 minutes with
increasing lanoteplase doses (P,0.001) (Table 2, Figure 1).
The proportion of subjects with TIMI grade 3 flow at 60
minutes with lanoteplase treatment increased from 23.6% in
the 15-kU/kg group to 47.1% in the 120-kU/kg group.
In addition, the proportion of patients who achieved TIMI
grade 3 flow at 60 minutes with alteplase was 37.4%. The
proportion of subjects with TIMI grade 3 flow was higher in
the 120-kU/kg lanoteplase group than in the alteplase group.
However, the 95% CI for the difference in rates included zero
(9.7%; 95% CI, 23.7% to 23%).
Secondary Efficacy and Other Outcome Measures
Similar to the results at 60 minutes, at 90 minutes there was
a statistically significant increase in the proportion of subjects
with TIMI grade 3 flow with increasing lanoteplase dose
(P,0.001) (Figure 2). The proportion of patients who
Figure 2. Dose-response effect of lanoteplase (15, 30, 60, 120
kU/kg) and accelerated alteplase on TIMI grades 2 (shaded
bars) and 3 (solid bars) flow at 90 minutes in patients with sus-
pected AMI.
TABLE 3. Summary of 30-Day Composite Clinical Outcome in Patients Randomized to
Receive Lanoteplase or Accelerated Alteplase
Clinical Outcome
No. of Patients (%) [95% CI]
Lanoteplase Dose (kU/kg)
15
(n5122)
30
(n5108)
60
(n5122)
120
(n5122)
Alteplase
(n5124)
Composite clinical outcome* 15 (12.3) 7 (6.5) 15 (12.3) 11 (9.0) 27 (21.8)
[7.0, 19.5] [2.6, 12.9] [7.0, 19.5] [4.6, 15.6] [14.9, 30.1]
Death 3 (2.5) 1 (0.9) 6 (4.9) 5 (4.1) 8 (6.5)
[0.5, 7.0] [0, 5.1] [1.8, 10.4] [1.3, 9.3] [2.8, 12.3]
Reinfarction 4 (3.3) 1 (0.9) 4 (3.3) 0 (0) 8 (6.5)
[0.9, 8.2] [0, 5.1] [0.9, 8.2] [0, 3.0] [2.8, 12.3]
Major bleeding 3 (2.4) 0 (0) 2 (1.6) 2 (1.6) 7† (5.6)
[0.5, 7.0] [0, 3.4] [0.2, 5.8] [0.2, 5.8] [2.3, 11.3]
Heart failure 8 (6.6) 5 (4.6) 7 (5.7) 6 (4.9) 11 (8.9)
[2.9, 12.5] [1.5, 10.5] [2.3, 11.5] [1.8, 10.4] [4.5, 15.3]
*Composite outcome indicates at least one unfavorable event.
†Includes 1 hemorrhagic stroke.
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achieved TIMI grade 3 flow 90 minutes after lanoteplase
increased from 26.1% after the 15-kU/kg dose to 57.1% after
the 120-kU/kg dose. The corresponding proportion of patients
in the alteplase group who achieved TIMI grade 3 flow at 90
minutes, 46.4%, was lower than the proportion in the 120-
kU/kg lanoteplase group (difference, 10.7%; 95% CI, 22.3%
to 23.7%).
Proportions of patients with TIMI grade 2 or 3 flow 90
minutes after lanoteplase increased from 54.1% after the
lowest dose to 83.0% after the highest dose (P,0.001, Figure
2). At the 120-kU/kg dose, lanoteplase was superior to
alteplase (71.4%) in restoring coronary patency at 90 minutes
(difference, 11.6%; 95% CI, 0.7% to 22.5%).
The proportion of subjects with TIMI grade 3 flow on days
3 to 6 ranged from 29.3% in the 15-kU/kg lanoteplase group
to 50.4% in the 120-kU/kg group. The proportion in the
alteplase group was 41.2%.
Tertiary Efficacy and Other Outcomes
The proportions of subjects with unfavorable composite
clinical outcomes ranged from 6.5% in the 30-kU/kg lanote-
plase group to 21.8% in the alteplase group without evidence
of a relationship between lanoteplase dose and outcome
(Table 3).
Safety
The numbers and percentages of subjects with adverse
clinical events before hospital discharge were comparable
among the lanoteplase and alteplase groups (Table 4). Bleed-
ing events were reported in 40.7% of subjects receiving any
dose of lanoteplase and in 54.0% of subjects receiving
alteplase. Major bleeding, defined as hemorrhagic stroke or
bleeding associated with hemodynamic compromise requir-
ing transfusion, occurred in 1.5% (7/479) of the lanoteplase-
treated subjects and in 5.6% (7/124) of subjects receiving
alteplase (Table 5). One intracranial hemorrhage and 1
thromboembolic stroke occurred in 2 subjects receiving
alteplase and in no subject in any lanoteplase group. Twenty-
three deaths occurred within 30 days of treatment, 15 (3.1%)
in the lanoteplase-treated groups and 8 (6.5%) in the alteplase
group.
Discussion
Lanoteplase is a rationally engineered derivative of tPA
that offers the combination of high potency, long half-life,
and prolonged clearance. Single-bolus, weight-adjusted
lanoteplase establishes complete perfusion (TIMI grade 3
flow) at 60 minutes in a dose-related fashion up to 120
kU/kg in patients with suspected AMI. Early, complete
infarct artery reperfusion at 60 minutes was chosen as the
primary end point on the basis of evidence that achieve-
ment of TIMI grade 3 flow in the infarct-related artery
improves survival.4,16
Lanoteplase at 120 kU/kg was as effective as alteplase in
establishing TIMI grade 2 or 3 flow at 60 minutes and
TABLE 4. Adverse Events Occurring in >7% of Patients Within Any Treatment
Group up to Hospital Discharge, Excluding Revascularizations
Adverse Event
Percent of Patients
Lanoteplase Dose (kU/kg)
15
(n5123)
30
(n5109)
60
(n5123)
120
(n5124)
Alteplase
(n5124)
Cardiovascular
Heart failure 7.3 6.4 8.9 8.1 8.9
Rhythm disturbance
Ventricular 15.4 17.4 17.9 15.3 17.7
Atrial 10.6 9.2 8.1 7.3 11.3
Bradycardia 8.9 3.7 2.4 6.5 4.0
Angina pectoris 14.6 11.9 8.9 10.5 12.1
Hypotension 12.2 12.8 5.7 12.1 8.1
Coronary artery disease 4.1 8.3 9.8 4.8 3.2
Neurological
Musculoskeletal pain 16.3 18.3 19.5 17.7 17.7
Headache 14.6 10.1 13.8 13.7 16.1
Anxiety/nervousness 10.6 11.0 14.6 13.7 12.9
Sleep disturbance 8.1 12.8 10.6 9.7 12.1
Gastrointestinal
Nausea/vomiting 19.5 15.6 9.8 12.1 14.5
Constipation 8.1 8.3 9.8 8.9 8.1
Other
Fever 14.6 12.8 11.4 10.5 13.7
General pain 7.3 10.1 4.9 6.5 8.9
Any adverse event 95.9 95.4 92.7 95.2 87.9
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superior in restoring TIMI grades 2 or 3 flow at 90 minutes.
The 30-day composite clinical outcome suggests that lanote-
plase was at least as effective as alteplase in reducing major
morbidity and mortality after AMI.
Major bleeding, particularly hemorrhagic stroke, is an
important safety issue with thrombolytics. In this trial, .90%
of patients experienced no bleeding or mild bleeding, usually
at the puncture site. Moderate and major bleeding was seen in
4.9% to 8.1% of patients in the lanoteplase groups and in
10.5% of alteplase subjects. Major bleeding occurred in 1.5%
of lanoteplase patients and 5.6% of alteplase patients (includ-
ing 1 hemorrhagic stroke).
The trend in recent trials toward inclusion of more elderly
and female patients, who tend to weigh less, has further
focused attention on appropriate dosing of thrombolytics.9
Early experience with alteplase suggested excessive bleeding
in light (,60 kg) patients and a trend toward decreased
thrombolytic efficacy in heavy individuals (.90 kg).17,18
Lanoteplase was administered as a weight-adjusted dose to
achieve optimal efficacy with minimal risk of bleeding.
Despite their efficacy in the treatment of AMI,
thrombolytic agents are underused. An additional 15% to
25% of patients could receive thrombolytic therapy.19 The
reasons for undertreatment are numerous, but they fall into 2
categories: presentation delay (time from onset of symptoms
to arrival at hospital) and treatment delay (time for the
medical care team to provide treatment).20 A single-bolus
thrombolytic agent should have an immediate impact on
treatment delay. Drug preparation and administration times
are cut to a minimum, with little conflict in the coadminis-
tration of other drugs through the same intravenous line. In
addition, a simple regimen reduces dosing error. Single-bolus
administration has also reactivated interest in prehospital
treatment with thrombolytics. Improvements in technology
are likely to support more aggressive treatment outside of the
hospital setting.21
Conclusions
Lanoteplase restores complete perfusion in the infarct-related
artery at 60 minutes in a dose-related manner in patients
presenting within 6 hours of suspected AMI. Although
InTIME was not large enough to completely define the safety
profile, in this study lanoteplase was well tolerated at 15 to
120 kU/kg. As expected with all thrombolytics, overall
bleeding was dose-related, with the incidence at the highest
dose, 120 kU/kg, comparable to that of alteplase. Serious
bleeding, which occurred in a small number of patients, and
other adverse events were not dose-related. At a dose of 120
kU/kg, lanoteplase produced early and sustained patency
more frequently than alteplase, with an encouraging trend
toward improvement in a 30-day composite clinical outcome.
InTIME was an angiographic dose-ranging trial that was
not designed to evaluate relative effects on mortality. A larger
study is necessary to determine whether single-bolus, weight-
adjusted, lanoteplase will achieve survival benefits, preserve
left ventricular function, and prevent heart failure. These
issues are being addressed in a 15 000-patient mortality
study, InTIME-II, comparing lanoteplase (120 kU/kg) with
accelerated alteplase.
Appendix
Participating Clinical Centers Listed by Country
Belgium
Hoˆpital de la Citadelle, Lie`ge: Jean Boland, MD (subinvestigator:
Jean-Luc Peters, MD; study nurses: Mireille Massoz, Philippe
Baumans); U.Z. Antwerpen, Edegem: Christiaan Vrints, MD (sub-
investigators: Herbert De Raedt, MD, Johan Bosmans, MD, Marc
Claeys, MD; study nurse: Tinneke Sysmans); St Jansziekenhuis,
Genk: Walter Van Mieghem, MD, Mathias Vrolix, MD (subinves-
tigator: Johan Van Lierde, MD; study nurse: Jacqueline Hollants);
Cliniques Universitaires de Mont- Godinne, Yvoir: Patrick Evrard,
MD (subinvestigator: Erwin Schroeder, MD); U.Z. Gent, Gent: Yves
Taeymans, MD (subinvestigator: Peter Gheeraert, MD; study coor-
dinator: Hermina Middendorp); C.H.U. du Sart Tilman, Lie`ge: Luc
Pierard, MD (subinvestigator: Lucien Finianos, MD); Hoˆpital
Erasme, Brussels: Eric Stoupel, MD (subinvestigator: Marc Renard,
MD; study nurse: Marie De Clippel).
Canada
Montreal Heart Institute, Montreal, Quebec: Pierre Theroux, MD
(subinvestigators: Jocelyn Dupuis, MD, Pierre de Guise, MD, Martin
Juneau, MD, Jean-Francois Tanquay, MD, B. Thibault, MD); Uni-
versity of Calgary Health Sciences Center, Calgary, Alberta:
Mouhieddin Traboulsi, MD (subinvestigators: Todd Anderson,
James Hansen, Merril Knudtson, David Roth, France Spence, Wayne
Warrica); University of Ottawa Heart Institute, Ottawa, Ontario:
Richard F. Davies, MD (subinvestigators: Rob Bealands, MD, Lyall
Higginson, MD, William L. Williams, MD, Marino Labinaz, MD,
Michel Lemay, MD, Jean-Francois Marquis, MD); Royal University
Hospital Saskatoon, Saskatchewan: J.D. McMeekin, MD (subinves-
tigator: J.F. Lopez, MD).
TABLE 5. Number and Percentage of Subjects With Bleeding Events by Severity
No. (%) of Subjects Who Experienced Bleeding
Treatment
No. of
Subjects None Mild Moderate
Hemodynamic
Compromise
Hemorrhagic
Stroke
Lanoteplase, kU/kg
15 123 82 (67) 34 (28) 4 (3) 3 (2) 0 (0)
30 109 72 (66) 29 (27) 8 (7) 0 (0) 0 (0)
60 123 74 (60) 43 (35) 4 (3) 2 (2) 0 (0)
120 124* 56 (45) 58 (47) 8 (6) 2 (2) 0 (0)
Alteplase 124 57 (46) 53 (43) 6 (5) 6 (5) 1 (0.8%)†
*Includes second exposure of twice randomized subject.
†A thomboembolic stroke also occurred in this group.
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France
Hoˆpital Pasteur, Nice: Marcel Baudouy, MD (subinvestigator: Emile
Ferrari, MD); Hoˆpital Universitaire Trousseau, Tours: Bernard
Charbonnier, MD (subinvestigator: Ge´rard Parcouret, MD); Hoˆpital
Universitaire Saint Jacques, Besanc¸on: Jean-Pierre Bassand, MD
(subinvestigators: Nicolas Meneveau, MD, Sanjiv Gupta, MD);
Hoˆpital Cochin, Paris: Simon Weber, MD (subinvestigator:
Khaldoum Benhamda, MD); Hoˆpital Necker, Paris: Andre´ Vach-
eron, MD (subinvestigators: Jean-Philippe Metzger, MD, Farzim
Beygui, MD); Hoˆpital Lariboisie`re, Paris: Philippe Beaufils, MD
(subinvestigator: Marc Brami, MD); Hoˆpital de Hautepierre, Stras-
bourg: Jean-Marie Mossard, MD (subinvestigators: Pierre Attali,
MD, Pierre Bareiss, MD, Jean Sacrez, MD); Hoˆpital St Jacques/G.
Montpied, Clermont Ferrand: Jean Cassagnes, MD (subinvestiga-
tors: Jean Rene´ Lusson, MD, Florent Briand, MD); Hoˆpital Vale`re
Lefebvre, Le Raincy: Simon Cattan, MD (subinvestigator: P.
Poirier, MD).
Germany
Universita¨tsklinik Homburg, Homburg/Saar: Gunther Berg, MD
(subinvestigators: Klaus Bonaventura, MD, Markus Muller, MD);
Universita¨t Heidelberg im Klinikum Mannheim, Mannheim: Paul
Gaudron, MD (subinvestigator: Ingrid Kugler, MD); Krankenhaus
Neuko¨lln, Berlin: Florian Forycki, MD; Stadtkrankenhaus Worms,
Worms: Peter Limbourg, DM (subinvestigators: Dick, MD, Horst
Mertes, MD, Ernst Roth, MD); Klinikum der Philipps-Universita¨t,
Marburg: Bernard Maisch, MD (subinvestigator: Hartmut Hesse,
MD); Universita¨tsklinikum Rudolph-Virchow, Berlin: Eckart Fleck,
MD Universita¨tsklinikum Benjamin Franklin, Berlin: Heinz-Peter
Schultheiss, MD (subinvestigator: Peter Schwimmbeck, MD); St-
Marien-Krankenhaus Siegen, Siegen: Peter Schuster, MD (subinves-
tigator: Hobbach, MD); Stiftsklinikum Augustinum, Mu¨nchen:
Rainer von Essen, MD (subinvestigators: Axel Reimer, MD, Michael
Roth, MD); Klinikum Aschaffenburg, Aschaffenburg: Rainer Uebis,
MD (subinvestigators: Matthias Stockmann, MD, Stefan Herzog,
MD); Krankenhaus der Barmherzigen Bru¨der, Regensburg: W.
Niederer, MD (subinvestigator: Josef Brandstetter, MD; study nurse:
Karin Fro¨hlich); Klinikum Lippe-Detmold GmbH, Detmold: Ulrich
Tebbe, MD (subinvestigator: Bernd Schulze, MD).
Israel
Heart Institute, Kaplan Hospital, Rehovot: Abraham Caspi, MD
(subinvestigators: O. Ayzenberg, MD, M. Swissa, MD).
Italy
Policlinico S. Chiara, Pisa: Andrea Biagini, MD (subinvestigators:
Sergio Berti, MD, Rita Bonini, MD); Ospedale Maggiore Borgot-
rento, Verona: Piero Zardini, MD (subinvestigators: Enrico Barbieri,
MD, Giorgio Morando, MD, Paolo Mario, MD); Ospedale Civile
Umberto I, Mestre: Antonio Raviele, MD (subinvestigators:
Francesco Di Pede, MD, Guerrino Zuin, MD); Universita` degli Studi
di Catania, Catania: Giuseppe Giuffrida, MD (subinvestigators:
Alfredo Galassi, MD, Giuseppe Cinnirella, MD); Ospedale Santa
Croce, Cuneo: Eugenio Uslenghi, MD (subinvestigators: Federica
Meinardi, MD, Giuseppe Steffenino, MD); Azienda Ospedaliera
Maggiore della Carita`, Novara: Carmelo Cernigliaro, MD; Ospedale
San Michele-Brotzu, Cagliari: Antonio Sanna, MD (subinvestiga-
tors: Giampaolo Scorcu, MD, Bruno Loy, MD).
Netherlands
University Hospital Groningen, Groningen: Peter den Heijer, MD
(subinvestigators: Ad van Boven, MD, Jaap Klijn, Margreet Oosterga,
J.O.J. Peels, MD, Trienke Steenhuis); Catharina Hospital, Eindhoven:
H.R. Michels, MD (subinvestigators: Hans Bonnier, MD, Clara
Hanekamp, MD, A. Spierings); Ignatius Ziekenhuis Breda, Breda:
H.M.A. Corbeij, MD (subinvestigators: Ulrick G. Chin-Ron-Sung, MD,
Jacqueline Konings); Sint Antonius Ziekenhuis, Nieuwegein: M.J.
Suttorp, MD (subinvestigators: J.C. Kelder, MD, Rosemary Lecluse,
MD, R. Van Der Schaaf, MD); Academic Hospital Maastricht, Maas-
tricht: Frank Vermeer, MD (subinvestigators: F. Bar, MD, Hetty Quint,
Jos Widdershoven, MD).
Poland
Klinika Kardiologii Pomorska Akademia Medyc¸na, Szczecin:
Zdzistawa Kornacewicz-Jach, MD (subinvestigators: Jarosław Gora¸cy,
MD, Robert Gil, MD, Jarosław Kaz´mierczak, MD); Go´rnos´la¸skie
Centrum Choro´b Serca, Zabrze: Stanisław Pasyk, MD (subinvesti-
gator: Zbigniew Kalarus, MD); Klinika Kardiologii Ogo´lnej, Instytut
Kardiologii Warszawa: Witold Ruzyłło, MD (subinvestigators: Marcin
Demkow, MD, Janina Ste¸pin´ska, MD); Klinika Kardiologii, Akademia
Medyczna Ło´dz´: Halina Bolin´ska, MD (subinvestigators: Maciej
Kos´mider, MD, Maciej Kuczborski, MD); I Klinika Choro´b
Wewne¸trznych, Instytut Medycyny Wewnetrznej, Warszawa:
Jerzy Adamus, MD (subinvestigators: Wojciech Kwiatkowski, MD,
Robert Olszewski, MD); Slaski Osrodek Kardiologii, Katowice: Maria
Trusz-Gluza, MD.
Spain
Hospital Gregorio Maran˜o´n, Madrid: Jose´ L. Lo´pez-Sendo´n, MD
(subinvestigators: Eulogio Garcı´a Ferna´ndez, MD, Esteban Lopez de
Sa, MD, Rafael Rubio, MD); Hospital Clinic I Provincial, Barcelona:
Amadeo Betrı´u Gibert, MD (subinvestigator: Antonio Serra, MD;
study nurse: Teresa Martorell).
Sweden
Akademiska Sjukhuset, Uppsala: Lars Wallentin, MD (subinvestiga-
tors: Bo Lagerqvist, MD, Erik Diderholm, MD; study nurse:
Gerd Alsjo).
Switzerland
Hoˆpital Cantonal, Gene`ve: Philip M. Urban, MD (subinvestigator:
Edoardo De Benedetti, MD).
United Kingdom
Western Infirmary, Glasgow, Scotland: W. Stewart Hillis, MD
(subinvestigators: Dougie Muir, MD, Gerry McCann, MD);
Hairmyres Hospital, Glasgow: Keith Oldroyd, MD (subinvestigator:
Barry D. Vallance, MD; study nurses: Jennifer Miller, Monica
Vallance); Royal Victoria Hospital, Belfast, Northern Ireland: Jennifer
Adgey, MD (subinvestigator: David Cochrane, MD; study nurse:
Yvonne McKay); Queen Elizabeth Hospital, Birmingham, England:
Nigel Buller, MD (subinvestigator: John Townend, MD).
United States
VA Medical Center, Houston, Tex: Mir Nadir Ali, MD; Redwood
City, Calif: Edward Anderson, MD (subinvestigators: Bruce A.
Benedick, MD, R. Hardwin Mead, MD, Michael A. Ruder, MD,
Nellis Smith, MD, Roger Winkle, MD); Spohn Hospital, Corpus
Christi, Tex: Raymond Graf, MD (subinvestigators: Joseph Garcia,
MD, Charles J. Schechter, MD, Stephen A. Turner, MD); Commu-
nity Hospital East, Indianapolis, Ind: Edward Harlamert, MD (sub-
investigators: Woodrow Corey, MD, Richard Hahn, MD, Blair
MacPhail, MD, Brad Weinberg, MD, Don Ziperman, MD); St
Mark’s Hospital, Salt Lake City, Utah: J. Joseph Perry, MD
(subinvestigators: D.C. Boorman, MD, T.S. Edwards, MD, E.W.
Ganellen, MD, R.W. Mackie, MD, G. Price, MD, K.G. Nielsen, MD,
K.L. Ritchie, MD); The Christ Hospital, Cincinnati, Ohio: John Paul
Runyon, MD (subinvestigators: Charles Abbottsmith, MD, Thomas
Broderick, MD, Peter Engel, MD, Charles Hattemer, MD, Dean J.
Kereiakes, MD, Eli Roth, MD, John F. Schneider, MD, Robert J.
Toltzis, MD, David Whang, MD); NE Baptist Hospital, San Antonio,
Tex: John F. Seaworth, MD (subinvestigators: Christopher W.
Casey, MD, Juan L. Garza, MD, Kevin F. James, MD, Edmond J.
Leroux, MD, Hal A. Martin, MD, Rene A. Oliveros, MD, Frank
Rubalcava, MD, Ted Trusevich, MD, Edwin J. Whitney, MD,
Richard F. Wilks, MD, David S. Wise, MD); University of Texas
Medical School–Houston: Richard W. Smalling, MD (subinvestiga-
tors: H.V. Anderson, MD, Ken Fujise, MD, Jacques Heibig, MD,
George Schroth, MD, James T. Willerson, MD); Brotman Medical
Center, Culver City, Calif: Ronald Karlsberg, MD (subinvestigator:
Steven Tabak, MD); Burns Clinic, Petoskey, Mich: W.L. Meengs,
MD (subinvestigators: H.T. Colfer, MD, P.E. Levanovich, MD, P.M.
Maloney, MD, D.W. Schuil, MD, H.J. Willens, MD); Columbia
Aurora Regional Medical Center, Aurora, Colo: Barry L. Molk, MD
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(subinvestigators: Dennis J. Battock, MD, Robert S. Baum, MD,
Andrew I. Cohen, MD, Joan E. Eldridge, MD, Steven P. Friedrich,
MD, Jerry H. Greenberg, MD, John M. Haas, MD, Nelson A. Prager,
MD, David Shander, MD); VA Medical Center, Oklahoma City,
Okla: Udho Thadani, MD (subinvestigators: Asim Chohan, MD,
Aaron Kugelmass, MD, Dwight Reynolds, MD, Eliot Schechter,
MD); Duluth Clinic, Duluth, Minn: Mark C. Neustel, MD (subin-
vestigators: Glenn Albin, MD, Carl E. Heltne, MD, James H.
Langager, MD, Michael J. Lucca, MD); University of Florida,
Gainesville: Carl Pepine, MD (subinvestigators: Barry Bertolet, MD,
C. Richard Conti, MD, Elizabeth Franco, RN, Eileen Handberg-
Thurmond, ARNP, James A. Hill, MD, Richard A. Kerensky, MD,
David Meurer, MD, Mark H. Mines, MD); Oklahoma Heart Institute,
Tulsa: Wayne Leimbach, MD (subinvestigators: John G. Ivanoff,
MD, Gregory D. Johnsen, MD, Son Phong Le, MD, Robert E.
Lynch, MD); Johns Hopkins Hospital, Baltimore, Md: Jeffrey
Brinker, MD (subinvestigators: Thomas Aversano, MD, Roger S.
Blumenthal, MD, Kathleen Citro, RN, Vicki J. Coombs, RN, MS,
CCRN, Audrey Dudek, RN, MS, Timothy Gardner, MD, Joel
Gellman, MD, Gary Gerstenbligh, MD, Sanford Gips, MD, Sean T.
Gloth, MD, Alan Heldman, MD, Karen Hicks, MD, Marco Meja,
MD, Alex Menkes, PA, Steven P. Schulman, MD, John R. Resar,
MD, Jeff Rade, MD, Mike Ronan, PA, David Thieman, MD, Calvin
Wells, MD); MediQuest Research Corp, Tampa, Fla: Robert
Feldman, MD (subinvestigators: Frank Hildner, MD, Brandi
Merchant, LPN, Joseph Sorrentino, RPH, Mary Standley, RN, Thomas
Wargovich, MD); Columbia Presbyterian Medical Center, New York,
NY: Hal S. Wasserman, MD (subinvestigators: Edith L. Escala, RN,
Kenneth Giedd, MD, Mark K. Warshofsky, MD); University of South
Florida, Tampa: J. Thompson Sullebarger, MD (subinvestigators: Juan
Aranda, MD, Lofty Basta, MD, Jan Brewington, MS, ARNP, Catherine
Carubba, MD, Saurabb Chokshi, MD, Robert Dalton, MD, George
Gamouras, MD, A. Sinan Gursoy, MD, David Hackstadt, MD, Eric
Harrison, MD, Margaret Keeler, MD, Ravi Khant, MD, Joel Kupfer,
MD, Linda Lewallen, MD, Fadi Matar, MD, Diane Matire, MD,
Stephen Mester, MD, Toni A. Mitchell, MD, George Monir, MD, Judy
Parker, RN, Ferdinand Richards, MD, Debbie Rinde-Hoffman, MD,
Rolando Rodriquez, MD, David Siegel, MD, Jeffrey Tauth, MD, Brian
Tiffany, MD, Julie Umberger, ARNP, Mark Weston, MD); Baptist
Health, Little Rock, Ark: Randal Hundley, MD (subinvestigators:
Amelia Burke, RN, Gary Collins, MD, Robert Lambert, MD, Vicki
Mabry, RN, Evelyn McKillip, LPN, James Shuffield Jr, MD); West
Jefferson Medical Center, Marrero, La: David B. Hutchinson, MD
(subinvestigators: Chester J. Falterman, MD, Louis B. Glade, MD,
Edmund K. Kerut, MD, Frederick G. Kushner, MD, Leslie W. Leven-
son, MD, Guy B. Mioton, MD); Medical Center of Delaware, Newark:
Michael E. Stillabower, MD; Mercy Hospital, San Diego, Calif: Jerrold
Glassman, MD (subinvestigators: Richard L. Blum, MD, Thomas Diggs
II, MD, Stewart L. Frank, MD, Richard G. Friedman, MD, Bruce
Kimura, MD, John H. Mazu, MD, John Morse, MD, Jeffery Mullvain,
MD, Ravindra Prabhu, MD, Joseph B. Stein, MD, David M. Stieber,
MD); Rochester General Hospital, Rochester, NY: Mark Thompson,
MD (subinvestigators: Eduardo A. Arazoza, MD, David Borowski, MD,
Luke Cheung, MD, Randal Christenson, MD, Vaughn DeForest, MD,
Robbin Dick, MD, Robert M. Easley, MD, Gerald M. Gacioch, MD,
David Isaacson, MD, Sunil Lulla, MD, Manju Morrissey, MD, Ray-
mond Ochrym, MD, David J. Oxley, MD, Thomas P. Stuver, MD,
Cynthia R. Reddeck, MD, Krishna Rao, MD, Sandra Sarooski-Roberts,
MD, Silke Schweidt, MD, Pamela Sullivan, MD, Alfredo Torres, MD);
Robert Wood Johnson Medical Center, New Brunswick, NJ: John
Kostis, MD (subinvestigators: Ziad Abbud, MD, Fabian Aurignac, MD,
Howard Blau, MD, Ronny Chadi, MD, Nancy Cristoforo, MD, Jeanne
DeMoss, DO, Rachana Kulkarni, MD, Anthony LoCurto, MD, Sebas-
tian Palmeri, MD, Desiree Reedus, MD, Khalil Suaray, MD); Slidell
Memorial Hospital, Slidell, La: Vasanth Bethala, MD (subinvestigators:
Amy Adams, LPN, Clara Bergeaux, RN, Victor Echenique, MD, Adesh
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ton, La: Miguel A. Gomez, MD (subinvestigators: Sheri Clunan, RN,
Umesh A. Patel, MD, Christy Robertson, CNMT, James E. Smith, MD,
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tal, Ormond Beach, Fla: John L. Walker, MD (subinvestigators: James
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Geoffrey Liss, MD, P. Natarajan, MD); William Beaumont Hospital,
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MD, Steven Almany, MD, Aaron Berman, MD, James Boatman, MD,
Marc Brodsky, MD, Alan Chernick, MD, Nishut Choksi, MD, David
Dobies, MD, Judith Feldman, MD, Harold Friedman, MD, V. Gan-
gadharan, MD, Mohammad Ghafouri, DO, Gerald Godfrey, MD, Lary
Goldman, MD, James Goldstein, MD, Richard Gordon, DO, Cindy
Grimes, MD, Ashok Gupta, MD, Raymond Jackson, MD, Joel Kahn,
MD, Steven Kororkin, MD, Robert Levin, MD, James London, MD,
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vestigators: William Herzog, MD, Samuel Rodriquez, MD, J. Lawrence
Stafford, MD, Andrew Ziskind, MD).
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